Plasmid DNA encoding neutralizing human monoclonal antibody without enhancing activity protects against dengue virus infection in mice

Nicotiana benthamiana as a potential source for producing anti-dengue virus D54 neutralizing therapeutic antibody

“…Currently, management of DENV infection is mainly based on symptomatic treatment and supportive care, which are insufficient in cases of severe dengue. Patients without access to adequate treatment have a mortality rate of 10–15 % [ 21 ]. Many researchers are currently working to develop mAbs against DENV for the treatment of severe dengue, such as dengue hemorrhagic fever or dengue shock syndrome.…”

“…Criteria for determining antibody neutralizing or enhancing activity were established based on the average plus standard deviation (SD) of the percentages of infected cells obtained from the six negative controls, which served as the baseline. An increase in the percentages of infected cells above the baseline indicates ADE, while a decrease below the baseline suggests neutralization activity [ 21 ].…”